# A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

> **NCT06218511** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 10 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Peptide-based hepatocellular carcinoma vaccine IMA970A
- **COMBINATION_PRODUCT:** Durvalumab
- **OTHER:** Montanide (Adjuvant)

## Key facts

- **NCT ID:** NCT06218511
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-22
- **Primary completion:** 2025-08-28
- **Final completion:** 2026-11
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06218511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06218511, "A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06218511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*